An interventional study of Dietary Phosphorus Intake in Chronic Kidney Disease (Stage 3-4) and Chronic Kidney Disease Mineral and Bone Disorder, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-28.
Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Renal Insufficiency, Chronic by University of Texas Southwestern Medical Center — 5 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · University of Texas Southwestern Medical Center.
Among the 11 studies in Renal Insufficiency, Chronic by University of Texas Southwestern Medical Center, this one is the only one that started in 2025, is one of 5 with no phase, and was the 9th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →5 of the 11 studies in Renal Insufficiency, Chronic by University of Texas Southwestern Medical Center are open now, in 1 country. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65 · Healthy volunteers
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 30–69
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 1
First in 2013; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 60 across the 8 interventional studies, 61 across the 3 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
2 of the studies in Renal Insufficiency, Chronic by University of Texas Southwestern Medical Center that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03565913Phase 3University of Texas Southwestern Medical CenterPotential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V | 2026-12-01 |
| NCT07368946University of Texas Southwestern Medical CenterPhosphate Assessment in Chronic Kidney Disease Patients Study | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Renal Insufficiency, Chronic by University of Texas Southwestern Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The proposed pilot feeding study aims to explore novel pathways in phosphate metabolism and identify new biomarkers, as well as to develop a compound index for assessing phosphate overload with high validity and reliability.
Investigators will address the following specific aims: 1). To explore novel pathways of phosphate metabolism and assess the influence of CKD status on these metabolic pathways. 2). To identify novel biomarkers for phosphate overload that reflect changes in dietary phosphorus intake. 3). To develop a compound phosphate overload index that measures dietary phosphorus intake with high validity and reliability.
This study will provide novel insights into phosphate metabolism and the assessment of phosphate overload in CKD patients. This investigation aims to provide preliminary data to further studies for the development of reliable biomarkers in CKD patients, which could contribute significantly to early interventions and improve health outcomes.
Specifically, study team propose recruiting 30 participants with CKD and 30 without CKD to investigate the responses of blood metabolites and known biomarkers to a 21-day diet intervention. The intervention will consist of a dietary phosphorus intake of about 777 mg/day for 7 days, followed by an increase to about 1,277mg/day for another 7 days, and a further increase to about 1,777 mg/day for the subsequent 7 days. 1200 mg/day and 1700 mg/day phosphorus diets will be achieved by providing participants with sodium phosphate capsules and 777 mg/day meals. The meal plan will maintain consistent intake of calories, sodium, potassium, and calcium throughout the 21-day intervention. Sodium, calcium, and potassium content will not change significantly throughout the intervention. The overnight fasting blood and 24-hour and random urine samples will be collected at the baseline and end of each phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with eGFR \>15 ml/min/1.73m2 - \< 60 ml/min/1.73m2 for the CKD group
Dietary Supplement: Dietary Phosphorus Intake
Healthy participants without CKD eGFR ≥ 60 ml/min/1.73m2
Dietary Supplement: Dietary Phosphorus Intake
Dietary phosphorus intake of about 777 mg/day for 7 days, followed by an increase to about 1,277mg/day for another 7 days, and a further increase to about 1,777 mg/day for the subsequent 7 days. The meal plan will maintain consistent intake of calories, sodium, potassium, and calcium throughout the 21-day intervention. 1200 mg/day and 1700 mg/day phosphorus diets will be achieved by providing participants with sodium phosphate capsules and 777 mg/day meals.
Change in serum phosphate levels
Circulating serum phosphate levels (mg/dL) will be measured using standard clinical laboratory assays
Time frame: Baseline, week 1, week 2, and week 3
Change in parathyroid hormone (PTH) levels
Circulating PTH levels (pg/mL) will be measured using standard clinical laboratory assays
Time frame: Baseline, week 1, week 2, and week 3
Change in C-terminal Fibroblast Growth Factor 23 (FGF23) levels
Circulating C-terminal FGF23 levels (RU/mL) will be measured using standard clinical laboratory assays
Time frame: Baseline, week 1, week 2, and week 3
Change in Fibroblast Growth Factor 23 (FGF23) levels
Circulating FGF23 levels (pg/mL) will be measured using standard clinical laboratory assays
Time frame: Baseline, week 1, week 2, and week 3
Phosphate burden indices
Phosphate burden indices, developed using machine learning methods to systematically incorporate both known biomarkers and novel biomarkers. No units have been identified, we anticipate creating a score.
Time frame: Baseline, week 1, week 2, week 3
Change in serum calcium levels
Circulating serum calcium levels (mg/dL) will be measured using standard clinical laboratory assays
Time frame: Baseline, week 1, week 2, and week 3
Change in Alkaline Phosphatase (ALP) levels
Circulating serum ALP levels (U/L) will be measured using standard clinical laboratory assays
Time frame: Baseline, week 1, week 2, and week 3
Change in 1,25-dihydroxyvitamin D levels
Circulating serum 1,25-dihydroxyvitamin D levels (pg/mL) will be measured using standard clinical laboratory assays
Time frame: Baseline, week 1, week 2, and week 3
Change in Bone-Specific Alkaline Phosphatase (BALP) levels
Circulating serum BALP levels (U/L) will be measured using standard clinical laboratory assays
Time frame: Baseline, week 1, week 2, and week 3
Change in urinary calcium levels
Circulating urinary calcium excretion levels (mg/day) will be measured using standardized laboratory urine assays
Time frame: Baseline, week 1, week 2, and week 3
Change in urinary phosphorus levels
Circulating urinary phosphorus excretion levels (mg/day) will be measured using standardized laboratory urine assays
Time frame: Baseline, week 1, week 2, and week 3
Exploratory: Phosphate-related biomarkers identified using proteomics platforms
For the proteomics analysis, only novel biomarkers associated with the phosphate diet will be reported, and their quantitative values are expressed as relative fluorescence units (RFU).
Time frame: Baseline, week 1, week 2, week 3
Exploratory: Phosphate-related biomarkers identified using metabolomics platforms
For the metabolomic analysis, only novel biomarkers associated with the phosphate diet will be reported. These features are not yet chemically identified, quantitative results are expressed as relative abundances.
Time frame: Baseline, week 1, week 2, week 3
Plan to share: Yes — IRB approval is required before sharing IPD.
Supporting information: Study protocol
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.
Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 19 months is below that.
Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
University of Texas Southwestern Medical Center →